Dana-Farber Cancer Institute | Strategic Alliance Partners

The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.

Drs Florez and Riess discuss the distinction between HER2 overexpression and HER2 mutations in non–small cell lung cancer.

Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant and the clinical role of the ctDNA-guided switch paradigm introduced by SERENA-6.

New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.

The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.

Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.

Giada Bianchi, MD, discusses the mechanism of action for anselamimab in AL amyloidosis.

Dana-Farber Cancer Institute is launching Solavia Decision Suite to bring clinical expertise and evidence-based treatment pathways directly into clinicians’ workflows.

First-line trastuzumab deruxtecan reduced the risk of progression or death by 37% compared with pembrolizumab plus chemotherapy in HER2-mutant non–small cell lung cancer.

A donation from Mario Germano Giuliani and Lisa Giuliani will support research in multiple myeloma at Dana-Farber Cancer Institute.

Brandon Huffman, MD, discusses INCB161734 and how the phase 3 DAWN-303 trial is testing it in metastatic pancreatic cancer.

During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.

The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.

Richard K. and Nancy K. Lubin have made a $35 million gift to Dana-Farber Cancer Institute’s Future of Cancer Care Fund.

Dana-Farber research aided in the FDA approval of iberdomide-based therapy in relapsed/refractory multiple myeloma.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

Narjust Florez, MD, discusses how the agenda for the Bridging the Gaps in Lung Cancer meeting evolves year to year based on emerging data and community feedback.

Paolo Tarantino, MD, PhD, discusses key data with ADCs in breast cancer that were presented at ASCO 2026.

Toni K. Choueiri, MD, discusses safety data from LITESPARK-022 in ccRCC.

Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma, a cancer with few treatment options, to identify new treatment vulnerabilities.

Sara M. Tolaney, MD, MPH, discusses research inspired by an analysis of first-line T-DXd plus pertuzumab in HER2-positive metastatic breast cancer.

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

Paolo Tarantino, MD, PhD, notes the emergence of TROP2-directed ADCs in first-line TNBC management and the sequencing questions their arrival raises.

Paolo Tarantino, MD, PhD, notes the implications of updated safety data with post-neoadjuvant T-DXd in high-risk, HER2-positive early breast cancer.

A collaborative research initiative will unite two comprehensive inflammatory breast cancer clinics.

Dr Tarantino discusses practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting.

Dr Tolaney discusses the FDA approval of first-line sacituzumab govitecan plus pembrolizumab for locally advanced or metastatic PD-L1–positive TNBC.

Narjust Florez, MD, discusses a trilingual, multidisciplinary workshop that was held at the 2026 ASCO Annual Meeting.

Narjust Florez, MD, discusses how the FDA approval of zidesamtinib in locally advanced or metastatic ROS1-positive NSCLC is an example of the fast pace of clinical oncology.

Alissa Cooper, MD, discusses evolving strategies for biomarker-driven patient selection with tarlatamab in small cell lung cancer.